Compliance with the Current NCCN Guidelines and Its Critical Role in Pancreatic Adenocarcinoma
Laboratory Medicine · 2023
DOI: 10.1093/labmed/lmac046 ↗Kurz gefasst
Leitlinie in der Zeitschrift Laboratory Medicine, 2023. Verfasst von Jeffrey M Petersen und 1 weiteren Autor:innen. Beteiligte Einrichtung: Corporal Michael J Crescenz Veteran Affairs Medical Center, Philadelphia, Pennsylvania, USA. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Adenocarcinoma. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 29 Literaturangaben.
Abstract (Originalsprache)
Objectives
Since 2019, the National Comprehensive Cancer Network (NCCN) has recommended genetic testing for patients diagnosed with pancreatic adenocarcinoma that includes universal germline testing and tumor gene profiling for metastatic, locally advanced, or recurrent disease. However, testing compliance with this guideline has not yet been published in the English literature.
Methods
A quality assurance/quality improvement retrospective review was done to identify patients diagnosed with pancreatic adenocarcinoma from January 2019 to February 2021 to include the patient’s clinical status and genetic test results.
Results
There were 20 patient cases identified with pancreatic adenocarcinoma. A total of 11 cases had molecular tumor gene profiling and microsatellite instability/mismatch repair (MSI/MMR) testing performed and 1 case had only MSI/MMR testing by immunohistochemistry performed. Only 3 patients of the 20 in total received germline testing.
Conclusion
There was a significant number of patients for whom tumor gene profiling or germline testing had never been attempted as per recommended NCCN guidelines.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Corporal Michael J Crescenz Veteran Affairs Medical Center, Philadelphia, Pennsylvania, USA.
- University of Pennsylvania Philadelphia, Pennsylvania, USA.
ORCID-Profile: Jeffrey M Petersen
Zitieren
APA
Petersen, J. M., & Jhala, D. N. (2023). Compliance with the Current NCCN Guidelines and Its Critical Role in Pancreatic Adenocarcinoma. Laboratory Medicine. https://doi.org/10.1093/labmed/lmac046
Vancouver
Petersen JM, Jhala DN. Compliance with the Current NCCN Guidelines and Its Critical Role in Pancreatic Adenocarcinoma. Laboratory Medicine. 2023. doi:10.1093/labmed/lmac046
BibTeX
@article{Petersen2023,
author = {Petersen, Jeffrey M and Jhala, Darshana N},
title = {Compliance with the Current NCCN Guidelines and Its Critical Role in Pancreatic Adenocarcinoma},
journal = {Laboratory Medicine},
year = {2023},
doi = {10.1093/labmed/lmac046}
}
EUVIMED